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Blended electrospinning with 
human liver extracellular matrix 
for engineering new hepatic 
microenvironments
Rhiannon Grant1, John Hallett2, stuart Forbes2, David Hay2 & Anthony Callanan1
tissue engineering of a transplantable liver could provide an alternative to donor livers for transplant, 
solving the problem of escalating donor shortages. one of the challenges for tissue engineers is the 
extracellular matrix (ECM); a finely controlled in vivo niche which supports hepatocytes. polymers and 
decellularized tissue scaffolds each provide some of the necessary biological cues for hepatocytes, 
however, neither alone has proved sufficient. Enhancing microenvironments using bioactive molecules 
allows researchers to create more appropriate niches for hepatocytes. We combined decellularized 
human liver tissue with electrospun polymers to produce a niche for hepatocytes and compared the 
human liver ECM to its individual components; Collagen I, Laminin-521 and Fibronectin. The resulting 
scaffolds were validated using THLE-3 hepatocytes. Immunohistochemistry confirmed retention of 
proteins in the scaffolds. Mechanical testing demonstrated significant increases in the Young’s Modulus 
of the decellularized ECM scaffold; providing significantly stiffer environments for hepatocytes. Each 
scaffold maintained hepatocyte growth, albumin production and influenced expression of key hepatic 
genes, with the decellularized ECM scaffolds exerting an influence which is not recapitulated by 
individual ECM components. Blended protein:polymer scaffolds provide a viable, translatable niche for 
hepatocytes and offers a solution to current obstacles in disease modelling and liver tissue engineering.
According to the NHS, liver disease is one of the top five causes of premature death in the UK, with incidence 
rising sharply by 20% over the last decade1. While liver disease incidence is rising, other top healthcare burdens, 
such as stroke, cancer, heart disease and lung disease mortality rates continue to fall2,3.
Liver disease’s hallmark pathology of late diagnosis and rapid acute disease progression leads to an urgent 
need for donor organs; the only curative treatment for end stage liver disease4. However, a chronic and ongoing 
shortage of suitable organs for transplant means many die before a donor liver can be found, and countless others 
live with severe, debilitating symptoms at a high cost to both the patient and the healthcare system2.
As part of the push for a solution to this problem, tissue engineers are focussing on creating niche microen-
vironments for main cell type of the liver, the hepatocyte, which support cell survival and function and could be 
used to treat patients in the future5–9. Such an environment would also allow for the study of new pharmaceuticals 
to treat human disease more effectively10. While research to date is making inroads into this dilemma, we are yet 
to see a lab created environment which accurately recapitulates the complex, finely tuned and responsive extra-
cellular matrix (ECM) of the liver11,12.
In an effort to address this, researchers have been incorporating bioactivity into scaffold environments for 
hepatocytes6,7,11. Decellularized extracellular matrix is the obvious avenue for such research13,14, and while results 
are promising a decellularized liver still requires a donor liver and recellularization. Obstacles such as necro-
sis, immune reaction and residual decellularization agents are all yet to be fully addressed for decellularized 
whole organs to be a truly viable option14–17. Individual ECM components in the form of gelatin18,19, collagen20–22, 
laminin23–25 and fibronectin26–28 have all been employed; each influencing the hepatocytes survival and func-
tion and providing insight into the complex cell-matrix interactions present in the hepatic microenvironment. 
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However each protein individually represents a small fraction of the bioactive molecules present in the ECM and 
when used in isolation cannot recapitulate the healthy hepatic matrix24,29,30.
With this work in mind we created a new scaffold for liver tissue engineering; for the first time incorporating 
human liver ECM (hLECM) directly into the fibres of electrospun polymer scaffolds. By combining the best 
of current scaffolding technology; reproducible polymeric scaffolds and efficiently decellularized human donor 
liver we have created a niche bioinfluential microenvironment which influences the function of cultured human 
hepatocytes.
Results
Our results demonstrate a method of incorporating proteins directly into a scaffold environment and of making 
impactful use of a valuable tissue resource which would otherwise be wasted. Protein:polymer scaffolds contain-
ing human liver ECM exert a significant positive influence on the gene expression profile, albumin production, 
attachment, and survival of liver cells which cannot be recapitulated by individual ECM components. These scaf-
folds show great potential not only for the future of liver tissue engineering and patient treatment, and are easily 
adaptable for other organs and tissues.
Mechanical characterization of scaffolds. Tensile testing revealed significant increases in the Young’s 
Modulus between the ECM scaffold and every other scaffold (Fig. 1), indicating that incorporating human liver 
ECM into the scaffold results in a significantly stiffer environment for hepatocytes. Interestingly, hRL521 scaffolds 
were significantly more elastic than both hBTC1 and hFN scaffolds (Table 1). Such results demonstrate that the 
mechanical influence of varying ECM compositions influence on cell behaviour and function cannot be dis-
counted in studies and must be considered when analysing biological results.
Histological characterisation of the scaffolds. The presence of the various proteins was demonstrated 
by immunohistochemistry performed on the scaffolds (Fig. 2). Collagen I, Laminin and Fibronectin were chosen 
because of their long established influence on hepatic cells29,31,32. Fibronectin is ubiquitous in healthy liver, col-
lagen I is the largest component of the healthy liver extracellular matrix and laminin is of particular importance 
in the differentiation of liver cells as well as for cell adhesion and liver regeneration11,33. Each is clearly present in 
their respective single protein scaffolds, as well as in varying degrees in the ECM scaffold, with no false positive 
staining observed in the control polymer only condition. Reassuringly, this indicates that the antigens to which 
the primary antibodies bind were not affected by the solubilisation or electrospinning process, and therefore that 
some bioactivity is maintained throughout the scaffold fabrication process.
Cell attachment and survival on scaffolds. Every scaffold maintains the survival of the THLE-3 liver 
cells and the number of cells increases significantly between each time point (Fig. 3A). Interestingly, between 
conditions the only significant difference observed is between the polymer only and hLECM scaffolds at day 5, 
with higher fluorescence observed on the hLECM scaffolds indicating that the presence of human liver ECM 
in the scaffold has a positive influence on the early expansion and/or survival and adherence of hepatocytes. 
Reassuringly, a similar pattern is observed in the DNA concentration (Fig. 3B) on the scaffolds, with a difference 
observed between polymer only and hLECM conditions once again; more DNA is present on the hLECM scaf-
folds indicating the presence of more cells. Live/dead viability/cytotoxicity images (Fig. 4) further demonstrate 
the continuing survival of the hepatocytes at the latest time point (16d), with a confluent population of viable 
Figure 1. Mechanical testing. Incorporating human liver ECM into the scaffold produces a significantly 
stiffer environment for hepatocytes. hRL521 scaffolds are significantly more elastic than both hBTC1 and 
hFN scaffolds. N = 6, Data shown as mean ± 95% confidence interval with statistics performed using One way 
ANOVA with Games Howell post hoc analyses.
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cells present on the scaffold and a low level of cell death on each scaffold. Presence of a dense cell layer is further 
confirmed by SEM imaging (Fig. 5), with a carpet of cells visible in each condition at 16d.
Gene expression of THLE-3s in response to hybrid polymer-ECM scaffolds. Genes associated with 
liver function were assayed for gene expression (Fig. 6). Additionally, genes for ECM expression were assayed. 
Albumin (Fig. 6A), a marker of appropriate adult hepatocyte differentiation and function, and Cytochrome 
P450s (CYP1A1 Fig. 6B, CYP1A2 Fig. 6C and CYP3A4 Fig. 6D), a family of enzymes involved in metabolism 
of drugs and other toxic compounds in the liver34–36 were both studied. Three ECM genes important in normal 
liver composition were also assayed24,33; Fibronectin (FN1 Fig. 6E), Collagen I (COL1A1 Fig. 6F) and Collagen 
IV (COL4A1 Fig. 6G). Considering the plastic nature of ECM, these genes are of interest with regards to ongo-
ing modification of the hepatic niche despite hepatocytes not being the sole producers of hepatic ECM33,37. 
Finally, expression of alpha-1 antitrypsin (AAT Supplementary Fig. 1A) and hepatocyte nuclear factor 4 (HNF 
Supplementary Fig. 1B) were tested. AAT is a serpin family protease inhibitor which protects tissues frim adverse 
effects of inflammatory enzymes released during immune responses38. HNF binds DNA and controls the expres-
sion of several hepatic genes39. Both genes are considered as markers of hepatic differentiation. Results were 
normalised to the polymer only condition to assay the influence of the protein component of the scaffolds on 
gene expression.
Only the human liver ECM scaffold maintains albumin expression in the expected pattern, increasing over 
time; as seen in primary hepatocytes and other liver cell lines40. CYP1A1 is consistently downregulated in 
Scaffold Polymer only hBTC1 hFN hRL521 ECM
Average Young’s 
Modulus (MPa) 11.11 ± 1.88 12.53 ± 1.96 13.2 ± 1.40 8.15 ± 1.35 18.49 ± 1.40
Table 1. Elasticity (0–10% strain).
Figure 2. Immunohistochemistry. Collagen I, Fibronectin and Laminin are all present in their respective single 
protein scaffolds, as well as in varying degrees in the ECM scaffold, with no false positive staining observed 
in the control polymer only condition. Stains were performed for Collagen I, Laminin and Fibronectin,post 
processed using ImageJ. 10x magnification.
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comparison to the polymer only scaffolds in every condition over the 16 days. CYP1A2 is down regulated in com-
parison to polymer only, with significant changes observed on hRL521 and hBTC1 scaffolds at day 16. CYP1A2 
is upregulated at day 16 on liver ECM, indicating an improvement in metabolic capability for hepatocytes grown 
in the hLECM scaffolds. All the single protein environments increase the expression of CYP3A4 in comparison 
to the polymer only environment. These changes in metabolic genes demonstrate the importance of protein 
microenvironment for hepatocyte function. hLECM scaffolds caused an increase in COL1A1 expression over the 
16 days, with expression 100 times higher at 16 days than on the polymer only environment. Significant changes 
were observed between days 5 and 10, and 10 and 16 of hFN and hRL521 scaffolds, and between days 5 and 16, 
and 10 and 16 on hBTC1 scaffolds. COL4A1 was downregulated over time on all the single protein scaffolds, but 
increases over time on the scaffolds which incorporate hLECM, although is overall reduced in comparison to 
Figure 3. Cell viability – Cell titre blue and picogreen DNA quantitation. Cell adherence was assessed by 
CellTiter-Blue® Cell viability assay (A) and further confirmed by Quant-IT™ Picogreen® dsDNA assay (B). 
Minimum n = 5. Data shown as mean ± 95% confidence interval with statistics performed using One-way 
ANOVA with Tukey post hoc testing. *p < 0.05 **p < 0.01, ***p < 0.001. Each condition maintains cell 
survival and the number of cells increases significantly between each time point (A). A significant increase in 
fluorescence is observed between the polymer only and hLECM scaffolds at day 5 indicating that the presence 
of human liver ECM has a positive influence on the early expansion and/or survival of hepatocytes. A consistent 
pattern is observed in the DNA concentration (B) on the scaffolds.
Figure 4. Cell viability – Live Dead. Live/Dead® Viability/Cytotoxicity staining analyses demonstrates 
continuing survival of the hepatocytes at the latest time point (16d), with a confluent population of viable cells 
and a low level of cell death on each scaffold. Results demonstrate the FL is viable at all assessed time points. 10x 
magnification.
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polymer only. Significant changes were observed between days 5 and 16 on hBTC1 and days 10 and 16 on hRL521 
scaffolds in FN1 expression. Reduction in expression of FN1 was slight in comparison to polymer only scaffolds. 
HNF and AAT expression are low as expected41 (Supplementary Fig. 1), however the relatively short culture 
period of 16d may not yet have revealed whether or not these cells are capable of mature hepatic gene expression.
Albumin production. Albumin levels are indicative of hepatic health in vivo and response to the cellular 
microenvironment7,29. hBTC1, polymer only and liver ECM all exhibit increasing production of albumin over 
time (Fig. 7), as expected in a healthy hepatocyte culture and correlating with gene expression patterns observed 
in Fig. 6. Interestingly, a significant increase in albumin production is observed on liver ECM scaffolds when 
compared with hRL521 scaffolds at day 10, and compared to hBTC1 scaffolds at day 5; indicating that hLECM 
is important for the production of albumin and that individual ECM components are not sufficient to boost the 
production of albumin.
Validation of tissue decellularization. Picogreen was employed to validate the decellularization process 
and ensure minimal DNA was present in the scaffolds. Results in Table 2 reassure us that our decellularization 
process is effective.
Discussion
A bioactive scaffold for hepatocyte culture is an important avenue for tissue engineering, meeting the need for 
an environment which supports the behaviour and function of hepatocytes in as close to an in vivo like state as 
possible. By manufacturing an optimised environment for hepatocytes we can address the need for appropriate 
in vitro models and the shortage of treatment options and donor livers for patients. By combining a valuable and 
underused resource such as human liver tissue with the reproducibility of polymeric scaffold manufacture we 
create a platform that can produce consistent, clinically translatable scaffolds for liver cell survival and function.
An electrospun fibre was chosen as the basis of these scaffolds as their fibrous nature mimics the morphology 
of native fibrillary collagen I in the liver extracellular matrix. PLA was used for this study because of its history of 
use in medical devices due to its biodegradation profile and compatibility with cellular environments. It is of note 
that the fibre diameter of each scaffold varied between proteins despite being electrospun under identical param-
eters. This method was employed to ensure the proteins were exposed to the same levels of electrical charge, 
solvent concentration and spinning time. The influence of fibre size when culturing upon electrospun scaffolds is 
yet to be fully elucidated, with evidence that variations between 0.3–1.3 µm do not influence cell behaviour42,43.
The livers used in this study are an underutilised resource. The donors are approved for transplant, but for 
varying reasons the liver may not be taken for transplant. In this situation, approved researchers are contacted 
and offered the tissue. Were we not to take the livers, they would be disposed of as clinical waste. This platform 
provides a method of using these livers to create niche, biologically active microenvironments for hepatocytes 
without the concerns that come with the more commonly used animal sourced tissue. Equally, the decellulariza-
tion process developed as part of this work is effective and importantly, does not rely upon an intact vasculature 
for efficient decellularization unlike other successful work. This means that traumatically injured livers which are 
beyond surgical repair, those with occluded vasculature or partial lobes of liver. While the field of whole organ 
decellularization is a promising avenue for tissue engineers, it remains that the field is hampered by a lack of 
suitable whole organs. This method circumvents the need for whole organs. The platform vastly enlarges the pool 
of tissue available for this avenue of research and makes use of a precious resource donated by bereaved families 
which would otherwise go to waste when unsuitable for transplant.
Our results indicate that hLECM has an influence on hepatocytes which cannot be recapitulated by individual 
ECM components, confirming that there is a complex and not fully understood relationship between cells and the 
native extracellular matrix. We have demonstrated that this method is robust, reproducible and that by harnessing 
ECM protein in conjunction with 3D scaffolding technologies we produce a bioactive scaffold, which significantly 
alters the behaviour of liver cells.
Figure 5. SEM characterization. The scaffolds were assessed for consistency and fibre size via scanning electron 
microscopy and subsequent image analysis. Fibres diameter was determined by DiameterJ 34, n = 4. 250x 
magnification. Presence of a dense cell layer is further confirmed by SEM imaging with a carpet of cells visible 
in each condition at 16d.
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ECM products are in clinical use, with products such as SIS, ALLO- PATCH HD®, MatriStem®, and 
Tutoplast® all being used in regenerative medicine for the benefit of patients. Equally, our decellularization 
method completely removed the potentially immunogenic DNA from the ECM, allaying translational concerns.
To assess scaffold performance we used THLE-3 cells, a non-tumorigenic line derived from the left lobe of 
a normal adult human liver44. These cells were chosen because they are not cancer cells, however are immortal-
ised and have been used in recent studies to represent non-tumourigenic hepatocytes45–48. While studies have 
debated the presence of CYP activity in THLE cells41, we propose that their non-tumourogenic growth pattern 
represented a test of scaffold biocompatibility with ‘normal’ hepatocytes, rather than with cancer derived cells. We 
assessed their adherence, growth and behaviour at 5, 10 and 16 days post-replating when cultured in vitro on the 
scaffolds containing hFN, hRL521, hBTC1 and hLECM versus scaffolds containing no protein; polymer only. We 
analysed cell attachment and viability, and gene expression of both liver function genes and ECM genes at both 5, 
Figure 6. Q-PCR of key hepatic genes. Quantitative analysis of gene expression was undertaken on the 
functional cell layer at five, ten and sixteen days of culture, compared to that of the same culture periods grown 
on polymer only scaffolds. mRNA levels of Albumin (A), Cyp1A1 (B), Cyp1A2 (C), CYP3A4 (D), Collagen I 
(E), and Collagen IV (F) and Fibronectin (G) are represented as fold difference relative to polymer only controls 
and relative to the housekeeping gene GAPDH. One-way ANOVA with Games Howell and Tukey post hoc 
testing and minimum n = 5. *p < 0.05 **p < 0.01, ***p < 0.001. Error bars = SD.
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10 and 16 day time points. Additionally, we validated the retention of ECM proteins in the scaffolds through the 
electrospinning process and the effective decellularization of the human liver ECM.
This work has resulted in a robust platform for the production of blended protein:polymer scaffolds and a 
reproducible method of liver decellularization which does not rely on obtaining an entire organ. We have created 
bioactive scaffold for liver tissue engineering which influence the behaviour of THLE-3 human hepatocytes. 
There is vast potential for the application of these scaffolds and methodology in the field of liver tissue engi-
neering and the wider tissue engineering community however further work is required to analyse the scaffolds 
influence on the cells and further improve the translatability of this work. While cell lines such as THLE-3s are 
undisputedly a highly valuable research resource, criticism of cell lines behaviour in vitro and the translatability of 
such results abounds within the scientific community44,49. It is important to undertake future work using primary 
or stem cell-derived hepatocytes50–54 and incorporate other important stimuli such as fluid flow to combat such 
criticism55–57. Furthermore, while the parenchymal hepatocytes make up more than 70% of the cellular mass, they 
do not exist in isolation and non-parenchymal and immune cells play an essential role in the in vivo liver; future 
studies should look to consider co-culture58–60.
We the researchers acknowledge the value of proteomic and functional assays (such as enzyme-linked immu-
nosorbent assays) in analysing the function of the hepatocytes in any future studies. At this juncture these tests 
were deemed unnecessary considering the critiques and heterogeneous behaviour of cell lines61–63 and focus of 
this work on the development of a novel biomaterial for liver tissue engineering. Additionally, while every care 
was taken to ensure the complete removal of decellularization agents in the manufacture of these scaffold, this 
should be validated to ensure further translatability of this work, considering the deleterious effects of remnant 
detergent on cells16,64,65.
While such concerns are valid, this work clearly demonstrates the potential of blended ECM scaffolds for liver 
tissue engineering, utilising an underused and valuable resource of human liver tissue rejected for transplant and 
provides a robust initial platform for further research.
This work established a robust platform for the production of reproducible blended protein:polymer scaffolds 
for liver tissue engineering by combining human liver ECM with electrospun polymer manufacturing technolo-
gies. To do so, we created a consistent and effective method of decellularizing the tissue using a pressurised flow 
device. We solubilized the ECM and incorporated it directly into the fibres via the electrospinning solution. We 
made additional scaffolds for comparison containing hFN, hBTC1 and hRL521. These were all compared to a 
scaffold manufactured with no protein. The protein:polymer scaffolds were seeded with a liver cell line to assess 
their biological influence. The work was validated using robust methods such as Q-PCR, mechanical quantifica-
tion, and SEM. Liver ECM containing protein:polymer scaffolds exert a significant positive influence on the gene 
expression profile, albumin production, attachment, and survival of liver cells.
Our results demonstrate great promise as a method of incorporating liver ECM and other proteins directly 
into a scaffold environment and of making impactful use of a valuable tissue resource which would otherwise 
be wasted. These scaffolds show great potential not only for the future of liver tissue engineering and patient 
Figure 7. Albumin production Serum. albumin produced by the THLE-3 cells over 24 hours at 5, 10 and 
16 day timepoints. n = 6. Data shown as mean ± 95% confidence interval with statistics performed using 
One-way ANOVA with Games Howell and Tukey post hoc testing and minimum n = 5. *p < 0.05 **p < 0.01, 
***p < 0.001.
Scaffold Native liver Decellularized liver Polymer only hBTC1 hFN hRL521 hLECM
DNA (ng p/mg) 340.57 0 0 0 0 0 0
Table 2. Remnant DNA in scaffolds.
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treatment, but are easily adaptable for other organs and tissues. Additionally, they are a useful tool for the devel-
opment of 3D liver cell platforms, which can be used for in vivo cell analysis and novel therapeutics research.
Materials and Methods
ethics and governance. All human tissue used in this study was provided by NHS Organ Donation and 
Transplant and NHS Blood and Transplant. No organs/tissues were procured from prisoners. Ethical approval 
was granted for the project from the North of Scotland Research Ethics Committee, ref 16/NS/0083. Informed 
consent for organ donation for research purposes was obtained in accordance with the Helsinki Declaration.
Decellularization. Decellularization of human liver tissue was performed at room temperature (19–22 °C) in 
a custom-made perfusion decellularization system (Fig. 8). Tissue was sliced into 3 mm thick sections and 35 mm 
diameter punches resected from the sections.
Tissue discs were placed in the decellularization device and secured between 70 µm stainless steel filtration 
mesh. A peristaltic pump (Watson Marlow 302 fixed speed pump) provided a flow rate of 200 ml/min. Pressure 
was adjusted to 24 mmHg using plasson pipes.
Tissue was subjected to an initial 4 hours of decellularization using 1 L of 0.5% sodium dodecyl sulphate 
(Sigma) in MilliQ H2O with 0.1% 100U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml Fungizone® (ampho-
tericin B) Anti-Anti solution (Gibco). After 4 hours, the decellularization solution was exchanged for fresh solu-
tion and the system ran overnight under the same conditions. The tissue was then washed with MilliQ H2O with 
0.1% 100U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml Fungizone® (amphotericin B) Anti-Anti solution 
(Gibco) for 4 hours and stored in sterile containers at −20 °C until use.
preparation of hLeCM. Decellularization was confirmed using the Quant-IT™ Picogreen® dsDNA assay 
kit (Life Technologies™), performed according to manufacturer’s instructions. The ECM was lyophilized in a 
FreeZone® 4.5 freeze-drier (Labconco®) before milling in a PM100® planetary ball mill (Retsch®).
preparation of proteins for electrospinning. The powdered hLECM was solubilized in 0.25 M acetic 
acid (Acros Organics) at a concentration of 25 µg per ml. Bornstein and Traub Type I collagen (Sigma Type VIII), 
powder from human placenta (hBTC1), human recombinant laminin 521 (hRL521) (Biolamina), and human 
plasma fibronectin (hFN) (Merck) were all solubilized and incorporated into the electrospinning solutions using 
the same methods. A control scaffold consisting of polymer only in the 9:1 HFIP:0.25 M acetic acid was also 
incorporated into the study.
preparation of electrospinning solutions. Methods henceforth were described previously in Grant et al.7  
and Grant et al.66. Briefly, a 22% wt/vol solution of poly-L-lactic acid (Goodman) and 9 ml hexafluoroisopropanol 
(Manchester Organics) was dissolved overnight at room temperature with agitation. 1 ml of 0.25 M acetic acid 
(Acros Organics) containing 25 µg protein was added to the 22% poly-L-lactic acid:HFIP solution and combined 
at room temperature under agitation for 1 hour.
electrospinning. Electrospinning was performed using a syringe pump EP-H11 (Harvard Apparatus) and an 
EC-DIG electrospinning system (IME technologies) via a 27G bore needle under the parameters noted in Table 3; 
Mandrels were coated in non-stick aluminium foil to collect the electrospun fibres. Fibre sheets were allowed to 
dry overnight in a fume hood and stored at 4 °C until use. Average fibre size of each scaffold type was as calculated 
using ImageJ plugin ‘DiameterJ’67 and is reported in Table 4.
Scaffold Preparation. 10 mm scaffold discs were cut using a biopsy punch. Scaffolds were submerged in 
30% isopropyl alcohol for 10 minutes, then subsequently rinsed three times in phosphate buffered saline for 
15 minutes each. Scaffolds were submerged in an antibiotic/antimycotic treatment solution of Dulbeccos Minimal 
Essential Media supplemented with 100U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml Fungizone® (ampho-
tericin B) Anti-Anti solution (Gibco) for 1 hour.
Cell seeding and Culture. THLE-3 cells were trypsinized using standard methods from tissue culture flasks 
and counted using the trypan blue exclusion method. 1 × 105 cells at passage 14 were suspended in 100 µl of com-
plete media and seeded directly on to the scaffolds. The cells were allowed adhere for 2 hours, then an additional 
400 µl of complete media was added.
Media was changed after 24 hours and changed every 48 hours subsequently. This functional layer (FL) of cells 
was cultured using standard methods for 5, 10 or 16 days at 37 °C and 5% CO2 in a humidified incubator.
Live/Dead® Viability/Cytotoxicity assay. Cell/scaffold constructs were incubated with 10 µm calcein 
and 2 µm ethidium homodimer-1 (Ethd-1) for 30 minutes as part of the two colour live/dead assay (Molecular 
Probes). The scaffolds were rinsed three times in CaCl2/MgCl2 free PBS to remove excess dye and placed onto 
a standard microscope slide with a 25 mm glass coverslip (VWR). All images were captured using a Zeiss Axio 
Imager fluorescent microscope (COIL, University of Edinburgh) at 40x magnification and post processed using 
ImageJ.
Celltiter-Blue® Cell viability assay. The assay was performed according to manufacturer’s instruction 
(Promega). For each condition group, minimum n = 5. Importantly, cell/scaffolds constructs were moved into 
fresh 48 well plates to prevent reading activity from tissue culture plastic bound cells. Measurements were read in 
a Modulus™ II microplate reader at an excitation wavelength of 525 nm and emission wavelength of 580–640 nm 
and reported as fluorescence.
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Albumin quantification. The bromocresol green (BCG) albumin assay (Sigma) was performed according 
to manufacturer’s instructions and was used to quantify serum albumin produced by the FL over 24 hours at 5, 
10 and 16 day time points. Results were read at an absorbance of 620 nm in a Modulus™ II microplate reader. For 
each condition group, minimum n = 5.
Figure 8. Decellularization device. Schematic of decellularization device which maintains pressurized flow to 
effectively decellularize tissue biopsies.
Volume 
per hour
Total 
volume
Mandrel:needle 
distance
Positive 
charge
Negative 
charge
Mandrel 
rotation
Needle 
movement
2.5 ml 7.5 ml 23 cm 16 kV −3 kV 300 rpm 100 mm/s
Table 3. Electrospinning parameters.
Scaffold Polymer only hBTC1 hFN hRL521 ECM
Average fibre Size (µm) 1.82 1.60 1.72 1.17 2.01
Table 4. Fibre sizes.
1 0Scientific RepoRts |          (2019) 9:6293  | https://doi.org/10.1038/s41598-019-42627-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
picogreen® DNA quantification. The Quant-IT Picogreen® dsDNA assay kit (Life Technologies™) was 
performed according to manufacturer instructions to establish the efficiency of the decellularization method and 
to estimate cell adherence and growth on the cell/scaffold constructs. Fluorescent intensity measurements were 
read in a Modulus™ II microplate reader (minimum n = 5) at an excitation wavelength of 480 nm and emission 
wavelength of 510–570 nm. A standard λ dsDNA curve of graded known concentrations was used to calibrate 
fluorescence intensity vs dsDNA concentration.
Immunohistochemistry. The samples were rinsed three times in PBS (Gibco) for 15 minutes each, then 
fixed in 4% v/v formalin buffered in saline for 1 hour at room temperature. Immunohistochemical staining was 
undertaken using antibodies for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma). All images 
were captured using a Zeiss Axio Imager system (Centre Optical Instrumentation Laboratory, University of 
Edinburgh) at 40x magnification and post processed using ImageJ.
scanning electron Microscopy. SEM was used to characterise the scaffold architecture. Samples were 
rinsed three times in PBS for 15 minutes each, then fixed in 2.5% v/v glutaraldehyde (Fisher Scientific) in 0.1 M 
phosphate buffer (PB) (pH 7.4) at 4 °C overnight. They were then rinsed three times in 0.1 M PB before being 
post-fixed in 1% v/v osmium tetroxide (Electron Microscopy Supplies) buffered with 0.1 M PB. Samples were 
again rinsed three times in 0.1 M PB and dehydrated through an ethanol gradient (30–100%). They were dried by 
placing them in hexamethyldisilazane (HMDS, Sigma) which was allowed to evaporate off at room temperature 
overnight. We mounted the samples onto SEM chucks using double sided carbon tape and coated them with a 
thin layer of gold and palladium alloy (Polaron Sputtercoater).
All images were captured at 5 kV using a Hitach S-4700 SEM (BioSEM, University of Edinburgh).
Mechanical testing. Tensile testing was undertaken to establish the dynamic properties of scaffolds and 
hLECM using the Instron 3367 dual column universal testing system with Bluehill 3 software. The system was fit-
ted with Instron biopulse submersible pneumatic side action grips and a 50 N load cell. A gauge length of 20 mm 
and an extension rate of 20 mm/min were used for all tensile tests. Analyses was conducted using the incremental 
modulus method as previously described68,69.
Six samples of each scaffold with a width of 10 mm and a gauge length of 80 mm were obtained from each 
sheet. Samples were fixed to ‘C’ shaped card templates to allow consistent set up during tensile testing. Samples 
were tested until failure. N = 6.
Gene expression analysis. All kits were used according to manufacturer’s instructions. RNA was extracted 
from FL cells using standard Trizol (Fisher Scientific) methods and purified using Qiagen’s RNeasy spin column 
system. cDNA was synthesised using the Promega ImProm-II™ Reverse Transcription System.
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the LightCycler® 480 
Instrument II (Roche Life Science) and Sensifast™ SYBR® High-ROX (Bioline) system. Results were normalized 
to THLE-3s of the same passage number grown on tissue culture plastic and compared to the housekeeping gene 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). Analysis was performed using the 2–[delta][delta] Ct 
method70,71, minimum n = 5. Albumin (Alb), Cytochrome P450 Family 1 Subfamily A Polypeptide 1 (Cyp1A1), 
Cytochrome P450 Family 1 Subfamily A Polypeptide 2 (Cyp1A2), Cytochrome P450 Family 3 Subfamily A 
Polypeptide 4 (Cyp3A4), Collagen Type I alpha 1 (Col1A1), Collagen Type 4 alpha 1 (Col4A1) and Fibronectin 
Type 1 (FN1), alpha-1 antitrypsin (AAT) and hepatocyte nuclear factor (HNF) were investigated, forward and 
reverse primers (Sigma) are detailed in Supplementary Table 1.
statistical analysis. One-way ANOVAs with Games-Howell and Tukey post-hoc testing was performed 
using Minitab 18 Statistical Software. Multiple comparisons tests were used following the Ryan Joiner test for 
normality and Bartlett’s test for the homogeneity of variances. The Tukey post hoc test was used where Bartlett’s 
test result is not significantly different i.e. the null hypothesis of population variances being equal is not rejected. 
The Games-Howell test does not assume equal variances and sample sizes and was performed on the ranked 
variables similar to other nonparametric tests. The Games-Howell post hoc test is used where Bartlett’s test 
result is significantly different i.e. the null hypothesis of population variances being equal is rejected. Error bars 
indicate standard deviation. A minimum of n = 3 and max of n = 6 was used for all analysis. *p value < 0.05, 
**p value < 0.01, ***p value < 0.001.
Data sharing. All data generated or analysed during this study are included in this published article (and its 
Supplementary Information files).
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